Hyundai Bioscience Co., Ltd.
http://www.hyundaibioscience.com/kor/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hyundai Bioscience Co., Ltd.
Monkeypox Vaccine, Drug Pipeline Grows Despite Signs Of Slowing Infections
Since its emergence in the spring, the monkeypox outbreak has spawned a small but growing pipeline of drugs and vaccines, many of them repurposed smallpox products.
Korean COVID-19 Contenders Still Racing Toward Finish Line
Hyundai Bioscience’s niclosamide-based oral antiviral moves into Phase II, joining other Korean COVID-19 treatment candidates in the pivotal trial stages, while SK Bioscience’s Phase III recombinant protein vaccine gears up for global market entry.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
- Other Names / Subsidiaries
-
- CNPharm, Inc., Hyundai Bioscience Inc., Hyundai IBT Co. Hyundai IT Co.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Hyundai Bioscience Co., Ltd.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice